• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

长效利匹韦林和卡博特韦治疗HIV-1感染的治疗药物监测——五例患者病例系列，其中一例在出现两类耐药后出现病毒学失败

Therapeutic Drug Monitoring of Long-Acting Rilpivirine and Cabotegravir for Treatment of HIV-1 Infection-A Case Series of Five Patients With One Virologic Failure After Development of Two-Class Resistance.

作者信息

Gerstenberg Jacob, Klinker Hartwig, Baier Michael, von Braun Amrei, Seybold Ulrich, Helbig Carlotta, Däumer Martin, Korn Klaus, Stephan Christoph, Schleenvoigt Benjamin T

机构信息

Institute for Tropical Medicine, Eberhard-Karls University Tübingen, Tübingen, Germany.

Division of Infectious Diseases, Department of Internal Medicine II, University of Würzburg Medical Center, Würzburg, Germany.

出版信息

Open Forum Infect Dis. 2024 Aug 23;11(9):ofae480. doi: 10.1093/ofid/ofae480. eCollection 2024 Sep.

DOI:10.1093/ofid/ofae480
PMID:39286033
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11403473/
Abstract

Virologic failure of long-acting rilpivirine/cabotegravir is rare but may result in severely limited treatment options. Known risk factors cannot predict all cases. Therapeutic drug monitoring (TDM) may help identify patients at risk, but reliable thresholds are missing. We report retrospective TDM in a cohort of 5 patients, including 1 virological failure.

摘要

长效rilpivirine/卡博特韦的病毒学失败情况罕见，但可能导致治疗选择严重受限。已知的风险因素无法预测所有病例。治疗药物监测（TDM）可能有助于识别有风险的患者，但缺乏可靠的阈值。我们报告了对5名患者队列的回顾性TDM，其中包括1例病毒学失败病例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c39f/11403473/521fe131ca9d/ofae480f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c39f/11403473/521fe131ca9d/ofae480f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c39f/11403473/521fe131ca9d/ofae480f1.jpg

相似文献

1
Therapeutic Drug Monitoring of Long-Acting Rilpivirine and Cabotegravir for Treatment of HIV-1 Infection-A Case Series of Five Patients With One Virologic Failure After Development of Two-Class Resistance.长效利匹韦林和卡博特韦治疗HIV-1感染的治疗药物监测——五例患者病例系列，其中一例在出现两类耐药后出现病毒学失败
Open Forum Infect Dis. 2024 Aug 23;11(9):ofae480. doi: 10.1093/ofid/ofae480. eCollection 2024 Sep.
2
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.长效肌内注射卡替拉韦和利匹韦林治疗成人 HIV-1 感染（LATTE-2）：一项随机、开放标签、2b 期、非劣效性试验的 96 周结果。
Lancet. 2017 Sep 23;390(10101):1499-1510. doi: 10.1016/S0140-6736(17)31917-7. Epub 2017 Jul 24.
3
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.长效卡替拉韦和利匹韦林每 2 个月给药 1 次用于治疗成人 HIV-1 感染（ATLAS-2M）：96 周结果：一项随机、多中心、开放性标签、3b 期、非劣效性研究。
Lancet HIV. 2021 Nov;8(11):e679-e689. doi: 10.1016/S2352-3018(21)00185-5. Epub 2021 Oct 11.
4
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.在感染 HIV-1 的成人中直接注射或口服先导药物启动长效卡替拉韦/利匹韦林：FLAIR 研究开放标签 3 期第 124 周结果。
Lancet HIV. 2021 Nov;8(11):e668-e678. doi: 10.1016/S2352-3018(21)00184-3. Epub 2021 Oct 14.
5
Cabotegravir: a novel HIV integrase inhibitor combined with rilpivirine as the first long-acting injectable program for the treatment of HIV infection.卡博特韦：一种新型HIV整合酶抑制剂，与利匹韦林联合使用，作为首个用于治疗HIV感染的长效注射方案。
Drugs Today (Barc). 2022 Dec;58(12):555-576. doi: 10.1358/dot.2022.58.12.3448340.
6
Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland.长效卡博特韦和rilpivirine的真实世界谷浓度及有效性：瑞士的一项多中心前瞻性观察研究
Lancet Reg Health Eur. 2023 Dec 13;36:100793. doi: 10.1016/j.lanepe.2023.100793. eCollection 2024 Jan.
7
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.长效卡博特韦和利匹韦林每 2 个月给药 1 次用于治疗 HIV-1 感染成人（ATLAS-2M）：48 周结果：一项随机、多中心、开放标签、3b 期、非劣效性研究。
Lancet. 2021 Dec 19;396(10267):1994-2005. doi: 10.1016/S0140-6736(20)32666-0. Epub 2020 Dec 9.
8
Guidance for the Interpretation of Long-Acting Cabotegravir and Rilpivirine Concentrations Based on Real-World Therapeutic Drug Monitoring Data and Documented Failures.基于真实世界治疗药物监测数据和已记录失败情况的长效卡博特韦和rilpivirine浓度解读指南。
Open Forum Infect Dis. 2024 Jan 16;11(2):ofae023. doi: 10.1093/ofid/ofae023. eCollection 2024 Feb.
9
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.长效卡博替拉韦加利匹韦林用于治疗成人 HIV-1 感染：随机、开放标签、3 期 FLAIR 研究的 96 周结果。
Lancet HIV. 2021 Apr;8(4):e185-e196. doi: 10.1016/S2352-3018(20)30340-4.
10
Favorable Virological Outcome, Characteristics of Injection Site Reactions, Decrease in Renal Function Biomarkers in Asian People with HIV Receiving Long-Acting Cabotegravir Plus Rilpivirine.亚洲 HIV 感染者接受长效卡替拉韦/利匹韦林治疗的病毒学结局良好，注射部位反应特征，肾功能生物标志物下降。
AIDS Res Hum Retroviruses. 2024 Apr;40(4):216-222. doi: 10.1089/AID.2023.0108. Epub 2024 Feb 1.

引用本文的文献

1
Sustained HIV Viral Suppression 18 Months After the Last Dose of Long-acting Cabotegravir/Rilpivirine: A Case Report.长效卡博特韦/利匹韦林最后一剂后18个月的持续HIV病毒抑制：一例报告
Open Forum Infect Dis. 2025 Jul 3;12(7):ofaf399. doi: 10.1093/ofid/ofaf399. eCollection 2025 Jul.

本文引用的文献

1
A HIV Superinfection Diagnosed in a Patient on Intramuscular Long-acting Combination of Cabotegravir and Rilpivirine.肌肉注射卡替拉韦和利匹韦林长效复方制剂的患者中诊断出的 HIV 合并感染。
Clin Infect Dis. 2024 Jul 19;79(1):196-197. doi: 10.1093/cid/ciad757.
2
Reply to Buzón-Martín and Troya.
Clin Infect Dis. 2025 Feb 5;80(1):231-232. doi: 10.1093/cid/ciae142.
3
Reasons Against Routine Determination of Plasma Trough Levels in People With HIV Treated With Intramuscular Long Acting Cabotegravir and Rilpivirine as of Today.
Clin Infect Dis. 2025 Feb 5;80(1):230-231. doi: 10.1093/cid/ciae141.
4
Guidance for the Interpretation of Long-Acting Cabotegravir and Rilpivirine Concentrations Based on Real-World Therapeutic Drug Monitoring Data and Documented Failures.基于真实世界治疗药物监测数据和已记录失败情况的长效卡博特韦和rilpivirine浓度解读指南。
Open Forum Infect Dis. 2024 Jan 16;11(2):ofae023. doi: 10.1093/ofid/ofae023. eCollection 2024 Feb.
5
Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis.长效卡替拉韦和利匹韦林注射剂转换后发生病毒学失败：深入分析。
Clin Infect Dis. 2024 Jul 19;79(1):189-195. doi: 10.1093/cid/ciae016.
6
Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland.长效卡博特韦和rilpivirine的真实世界谷浓度及有效性：瑞士的一项多中心前瞻性观察研究
Lancet Reg Health Eur. 2023 Dec 13;36:100793. doi: 10.1016/j.lanepe.2023.100793. eCollection 2024 Jan.
7
Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort.在美国，用于治疗HIV的卡博特韦+利匹韦林长效注射剂：来自OPERA队列的真实世界数据。
Infect Dis Ther. 2023 Dec;12(12):2807-2817. doi: 10.1007/s40121-023-00890-2. Epub 2023 Nov 15.
8
Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023.2023 年欧洲艾滋病临床学会指南 12.0 重大修订版。
HIV Med. 2023 Nov;24(11):1126-1136. doi: 10.1111/hiv.13542. Epub 2023 Oct 18.
9
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.扩展多变量模型以辅助长效卡替拉韦+利匹韦林治疗的患者选择：与病毒学失败相关的患者、药物浓度和病毒因素组合的临床效用。
Clin Infect Dis. 2023 Nov 17;77(10):1423-1431. doi: 10.1093/cid/ciad370.
10
Comparable Activities of Second-Generation HIV-1 Integrase Strand Transfer Inhibitors (INSTIs) on HIV-1 Clinical Isolates with INSTI Resistance Mutations.具有整合酶抑制剂耐药突变的 HIV-1 临床分离株中第二代 HIV-1 整合酶链转移抑制剂（INSTIs）的可比活性。
Antimicrob Agents Chemother. 2019 Dec 20;64(1). doi: 10.1128/AAC.01717-19.